These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

58 related items for PubMed ID: 8018978

  • 21. Gastric cyto-secretory correlations in peptic ulcer.
    Testino G, Cornaggia M, Valentini M.
    Hepatogastroenterology; 1999; 46(28):2710-2. PubMed ID: 10522069
    [Abstract] [Full Text] [Related]

  • 22. Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients.
    Moreno JA, Pajares JM, Santander C, Carpintero P, Hermida C, Lara S, García Grávalos R.
    J Gastroenterol; 1996 Nov; 31 Suppl 9():48-52. PubMed ID: 8959519
    [Abstract] [Full Text] [Related]

  • 23. Helicobacter pylori infection after gastrectomy and vagotomy in duodenal ulcer patients.
    Sito E, Konturek PC, Konturek SJ, Bielański W, Stachura J.
    J Physiol Pharmacol; 1996 Mar; 47(1):229-37. PubMed ID: 8777304
    [Abstract] [Full Text] [Related]

  • 24. Changes in the histology and function of gastric mucosa and in Helicobacter pylori colonization during a long-term follow-up period after vagotomy in duodenal ulcer patients.
    Peetsalu M, Valle J, Härkönen M, Maaroos HI, Peetsalu A.
    Hepatogastroenterology; 2005 Mar; 52(63):785-91. PubMed ID: 15966205
    [Abstract] [Full Text] [Related]

  • 25. Gastric mucosal expression and luminal release of growth factors in gastric carcinoma and duodenal ulcer patients before and after eradication of Helicobacter pylori.
    Konturek PC, Bielański W, Bobrzyński A, Hahn EG, Konturek SJ.
    J Physiol Pharmacol; 1997 Sep; 48(3):375-82. PubMed ID: 9376620
    [Abstract] [Full Text] [Related]

  • 26. Salivary and gastric luminal release of epidermal growth factor under basal conditions and after pentagastrin stimulation in healthy subjects and in duodenal ulcer patients before and after eradication of Helicobacter pylori.
    Konturek PC, Ernst H, Konturek J, Bobrzyński A, Kwiecień N, Faller G, Gedliczka O, Hahn EG.
    J Physiol Pharmacol; 1996 Mar; 47(1):187-94. PubMed ID: 8777298
    [Abstract] [Full Text] [Related]

  • 27. Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease.
    Kamada T, Hata J, Kusunoki H, Sugiu K, Ito M, Tanaka S, Kawamura Y, Chayama K, Haruma K.
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():99-104. PubMed ID: 15943855
    [Abstract] [Full Text] [Related]

  • 28. [The characteristics of peptic ulcer in subjects with concomitant ischemic heart disease].
    Loginov AS, Zvenigorodskaia LA, Potapova VB, Arbuzova VG, Korzhikov VV, Nilova TV.
    Ter Arkh; 1998 Jun; 70(2):9-13. PubMed ID: 9551561
    [Abstract] [Full Text] [Related]

  • 29. Site of peptic ulcer. comparison of hydrochloric acid output, pepsinogen and gastrin serum levels.
    Engler-Pinto Júnior P, Gama-Rodrigues J, Lopasso FP, Cordeiro AC, Saez-Alquezar A, Laudanna AA, Pinotti HW.
    Hepatogastroenterology; 1996 Jun; 43(12):1671-7. PubMed ID: 8975987
    [Abstract] [Full Text] [Related]

  • 30. Eradication of Helicobacter pylori and gastrin-somatostatin link in duodenal ulcer patients.
    Konturek JW, Bielański W, Konturek SJ, Domschke W.
    J Physiol Pharmacol; 1996 Mar; 47(1):161-75. PubMed ID: 8777296
    [Abstract] [Full Text] [Related]

  • 31. Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial.
    Higuchi K, Watanabe T, Tominaga K, Shiba M, Nakagawa K, Uno H, Kitada K, Satoh H, Chono S, Uchida T, Fujiwara Y, Arakawa T.
    Int J Clin Pharmacol Res; 2005 Mar; 25(4):187-94. PubMed ID: 16402635
    [Abstract] [Full Text] [Related]

  • 32. Helicobacter pylori-negative peptic ulcer in Japan: which contributes most to peptic ulcer development, Helicobacter pylori, NSAIDS or stress?
    Aoyama N, Shinoda Y, Matsushima Y, Shirasaka D, Kinoshita Y, Kasuga M, Chiba T.
    J Gastroenterol; 2000 Mar; 35 Suppl 12():33-7. PubMed ID: 10779215
    [Abstract] [Full Text] [Related]

  • 33. Increased risk for Helicobacter pylori recurrence by continuous acid suppression: a randomized controlled study.
    Manes G, Domínguez-Muñoz JE, Uomo G, Labenz J, Hackelsberger A, Malfertheiner P.
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):28-33. PubMed ID: 9615260
    [Abstract] [Full Text] [Related]

  • 34. Potential role for matrix metalloproteinase-3 in gastric ulcer healing.
    Tomita M, Ando T, Minami M, Watanabe O, Ishiguro K, Hasegawa M, Miyake N, Kondo S, Kato T, Miyahara R, Ohmiya N, Niwa Y, Goto H.
    Digestion; 2009 Feb; 79(1):23-9. PubMed ID: 19246917
    [Abstract] [Full Text] [Related]

  • 35. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial.
    Feldman M, Cryer B, Mallat D, Go MF.
    Am J Gastroenterol; 2001 Jun; 96(6):1751-7. PubMed ID: 11419825
    [Abstract] [Full Text] [Related]

  • 36. Clinical relevance of Helicobacter pylori CagA-positive strains: gastroduodenal peptic lesions marker.
    Martín Guerrero JM, Hergueta Delgado P, Esteban Carretero J, Romero Castro R, Pellicer Bautista FJ, Herrerías Gutiérrez JM.
    Rev Esp Enferm Dig; 2000 Mar; 92(3):160-73. PubMed ID: 10799946
    [Abstract] [Full Text] [Related]

  • 37. [Blood flow and morphofunctional status of gastroduodenal mucosa in different phases of peptic ulcer].
    Maev IV, Gorban' VV, Salova LM.
    Ter Arkh; 2007 Mar; 79(8):57-61. PubMed ID: 17926473
    [Abstract] [Full Text] [Related]

  • 38. Markers of slow-healing peptic ulcer in the elderly. A study on 1,052 ranitidine-treated patients.
    Battaglia G, Di Mario F, Dotto P, Leandro G, Pilotto A, Ferrana M, Vianello F, Vigneri S, Colonna CV, Naccarato R.
    Dig Dis Sci; 1993 Aug; 38(8):1414-21. PubMed ID: 8344096
    [Abstract] [Full Text] [Related]

  • 39. [Famotidine in the treatment of gastroduodenal ulcer].
    Lengyel G, Fehér J.
    Orv Hetil; 1994 Oct 16; 135(42):2299-304. PubMed ID: 7970643
    [Abstract] [Full Text] [Related]

  • 40. Serum pepsinogen I and pepsinogen II, and the ratio of pepsinogen I/pepsinogen II in peptic ulcer diseases: with special emphasis on the influence of the location of the ulcer crater.
    Wu MS, Wang HP, Wang JT, Wang TH, Lin JT.
    J Gastroenterol Hepatol; 1995 Oct 16; 10(4):401-4. PubMed ID: 8527705
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.